|

PRA-216 COPD Safety and Biomarker Study

RECRUITINGPhase 2Sponsored by Prana Therapies Inc
Actively Recruiting
PhasePhase 2
SponsorPrana Therapies Inc
Started2026-08-25
Est. completion2027-06-01
Eligibility
Age40 Years – 80 Years
Healthy vol.Accepted

Summary

This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with chronic obstructive pulmonary disease (COPD).

Eligibility

Age: 40 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age 40-80
* Willing and able to attend all study visits, comply with study requirements.
* Able and willing to provide written informed consent
* Documented COPD diagnosis prior for at least 12 months prior to screening.
* Currently receiving maintenance COPD medications at a stable dose for at least 3 months prior to visit 1

Exclusion Criteria:

* Evidence of clinically significant pulmonary condition or disease other than COPD
* Any physical or psychological condition that prohibits study completion
* Known history of illicit drug use or alcoholism within 12 months prior to the first dose of study agent
* History of severe allergic reactions or hypersensitivity
* Major surgery occurring within 8 weeks months prior to first dose of investigational product.
* Use of any marketed or investigational monoclonal or polyclonal antibody therapy within 4 months or 5 half-lives prior to visit 1.

Conditions2

COPDChronic Obstructive Pulmonary Disease (COPD)

Interventions1

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.